INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline that was also much larger than a control saline injection Copies of the ...
SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback